Loading organizations...
§ Venture Capital · CA, USA
Biotech investment firm creating spin-out companies to advance in-licensed drug candidates through Phase II clinical trials for unmet needs.
Based in Oakland, California, Aditum Bio is a biotechnology investment firm that in-licenses stalled preclinical drug candidates and forms spin-out companies to advance them through Phase II clinical trials. The firm operates an incubator model to accelerate drug development for large patient populations targeting unmet medical needs, managing over $900 million in total assets under management across three funds. In May 2024, the firm closed its third fund with $400 million in capital commitments to continue building its portfolio of more than ten distinct startups. Aditum Bio has launched several specialized therapeutics companies, including portfolio startups Tempero Bio, Vitalli Bio, and Versanis Bio, the latter of which was acquired by Eli Lilly for up to $1.925 billion in 2023. The organization was founded in 2019 by former Novartis executives Joe Jimenez and Dr. Mark Fishman.
Key people at Aditum Bio.
Aditum Bio was founded in 2019 by Susie Phillips (Executive Assistant to Co-Founder and Managing Director).
Aditum Bio was founded in 2019 by Susie Phillips (Executive Assistant to Co-Founder and Managing Director).
Key people at Aditum Bio.
Aditum Bio is a biotech venture capital firm founded in 2019 that specializes in rapidly translating scientific discoveries into innovative new medicines, focusing on the translational phase of drug development. It targets clinic-ready therapies, especially for underserved patient populations, by forming and staffing companies with medical and scientific experts to develop best-in-class therapies across a broad range of diseases. Their mission is to improve patient access to medicines that might otherwise not be developed, combining deep scientific expertise with agile operational capabilities to accelerate drug development and deliver faster returns for investors[1][2][5].
Founded by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research Dr. Mark Fishman, Aditum Bio leverages their leadership and domain expertise to identify promising drug candidates with unrecognized potential. The firm has launched multiple funds since inception (Fund I in 2019, Fund II in 2021, Fund III in 2024) and has spun out thirteen companies, including the notable sale of Versanis to Eli Lilly for $1.9 billion in 2023. This origin story highlights a strategic focus on bridging the gap between scientific discovery and clinical application through an innovative venture capital model[2][5][6].
Aditum Bio rides the trend of specialized biotech venture capital that bridges the traditional gap between early scientific discovery and clinical development, a phase often underfunded or inefficiently managed by conventional pharma or VC models. The timing is critical as advances in biomedical science generate numerous promising drug candidates requiring agile, expert-driven translational efforts to reach patients faster. Market forces favor firms like Aditum that can reduce development timelines and costs while addressing unmet medical needs, thus influencing the broader biotech ecosystem by accelerating innovation and improving patient outcomes[1][2][4].
Looking ahead, Aditum Bio is poised to expand its portfolio and impact by continuing to deploy capital and operational resources into translational-stage biotech companies. Trends such as precision medicine, immunology, and rare diseases will likely shape their investment focus. Their influence may grow as a model for how venture capital can integrate scientific rigor with operational agility to deliver both patient benefits and investor returns more efficiently. This positions Aditum Bio as a key player in evolving biotech venture capital toward a more patient- and science-driven future[1][6].
